| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/PGS.16.31 |
| P698 | PubMed publication ID | 27967318 |
| P2093 | author name string | Feng Qiu | |
| Mei Liu | |||
| Guofei Li | |||
| Xiujun Wu | |||
| Limei Zhao | |||
| Jingkai Gu | |||
| Guilian Zhao | |||
| P2860 | cites work | Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. | Q54580627 |
| Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers:gut hydrolysis of lovastatin is twice that of simvastatin. | Q55110775 | ||
| Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males | Q57500331 | ||
| Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin | Q57825140 | ||
| SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid | Q57825144 | ||
| SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin | Q57825149 | ||
| The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions | Q24310512 | ||
| The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants | Q28201500 | ||
| Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients | Q28538933 | ||
| Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes. | Q30357429 | ||
| Determination of lovastatin in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry | Q33315403 | ||
| The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients | Q33628473 | ||
| PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin | Q34129977 | ||
| CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort | Q34160942 | ||
| Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance | Q34309475 | ||
| Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? | Q34478635 | ||
| Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment | Q34561428 | ||
| Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse | Q35002429 | ||
| CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control | Q36927210 | ||
| No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin | Q37399440 | ||
| Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs | Q37481450 | ||
| Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin | Q37646573 | ||
| Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients | Q37728891 | ||
| Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis | Q38348120 | ||
| Efficacy and long-term adverse effect pattern of lovastatin | Q39539391 | ||
| Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells | Q39684954 | ||
| Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding | Q39737247 | ||
| Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression | Q42519981 | ||
| Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy | Q43267291 | ||
| Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia | Q43826505 | ||
| Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. | Q45912416 | ||
| ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. | Q45993642 | ||
| ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. | Q46111557 | ||
| PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo | Q46366046 | ||
| CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin | Q46557943 | ||
| Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. | Q47820302 | ||
| Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. | Q52569931 | ||
| Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? | Q53611791 | ||
| Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. | Q53968585 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 65-75 | |
| P577 | publication date | 2016-12-14 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers. | |
| P478 | volume | 18 |
Search more.